Several anti-IL-23p19-specific antibodies have undergone or are presently undertaking clinical studies for IBD, such as brazikumab, risankizumab, mirikizumab, and guselkumab (124–127). The gene discussed is IL23A; the disease is inflammatory bowel disease.